Sonnet BioTherapeutics (SONN)
(Delayed Data from NSDQ)
$0.86 USD
-0.01 (-1.00%)
Updated Jul 25, 2024 10:11 AM ET
2-Buy of 5 2
F Value D Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Sonnet BioTherapeutics Holdings, Inc. [SONN]
Reports for Purchase
Showing records 1 - 8 ( 8 total )
Company: Sonnet BioTherapeutics Holdings, Inc.
Industry: Retail - Restaurants
Company: Sonnet BioTherapeutics Holdings, Inc.
Industry: Retail - Restaurants
FDA Greenlights IND for SON-1010 for Treatment of Advanced Solid Tumors; Phase 1 Study to Begin in 2Q 2022.
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Sonnet BioTherapeutics Holdings, Inc.
Industry: Retail - Restaurants
Preclinical Data Presentation at AACR Supports Expectations of Superior Anti-Tumor Efficacy of Bispecific IL-FHAB
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Sonnet BioTherapeutics Holdings, Inc.
Industry: Retail - Restaurants
Deep Dive on Engineered Cytokines; Using Modern Technology to Teach Old Dogs New Tricks
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Sonnet BioTherapeutics Holdings, Inc.
Industry: Retail - Restaurants
Sonnet Provides F1Q 2022 Earnings and Business Update; Clinical Trials for SON-1010 and SON-080 on Track for 2Q22 Launch
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Sonnet BioTherapeutics Holdings, Inc.
Industry: Retail - Restaurants
Sonnet Announces Results for FY2021; Signs Abound for Catalyst-Rich 2022 and Beyond.
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Sonnet BioTherapeutics Holdings, Inc.
Industry: Retail - Restaurants
We initiate with a Buy rating and $2 price target
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Sonnet BioTherapeutics Holdings, Inc.
Industry: Retail - Restaurants
|